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1. Introduction 
Conventional gene therapies still require improvement in various respects, such as 
transfection efficiency for targeting organs or tissues, safety (Li Q et al., 2001; Pfeifer A & 
Verma IM, 2001; Watson DJ et al., 2002), and so on. For example, transfection of naked 
plasmid DNA requires the use of a large quantity of DNA because of enzymatic 
degradation in the human body. Conventional non-viral vectors seem to be inferior to 
viral ones in efficiency, except for nucleofection (Nishikawa M & Hashida M, 2002; 
Schakowski F et al., 2004). On the other hand, gene therapy using viral vectors such as 
adenovirus, retrovirus etc., may induce tissue inflammation (Tomasoni S & Benigni A, 
2004), though the efficiency of transfection is often relatively high. Also, the safety of viral 
transfection remains an issue, because of the risk of toxicity or mutation of viruses (Ferber 
D, 2001; Isner JM, 2002; Kay MA et al., 2001). Moreover, in vivo gene delivery to localized 
target tissues usually necessitates an invasive approach; for example, direct gene 
transfection to cardiomyocytes requires a surgical approach (Losordo DW et al.,1998) or 
catheterization (Kornowski R et al., 2000; Laitinen M et al., 2000). On the other hand, ex 
vivo gene transfection is less invasive. However, targeting of specific tissues by 
intravenous injection is usually inefficient. 
Macrophages accumulate in ischemic tissues through chemotaxis (Ramsay SC et al., 1992). 
Therefore, we considered that intravenously administered macrophages might target 
ischemic tissue in vivo. Tabata, et al. reported that particles of gelatin are phagocytized by 
macrophages (Tabata Y & Ikada Y, 1987; Tabata Y & Ikada Y, 1988). Gelatin is a natural 
polymer derived from collagen, and is widely used in pharmaceutical or medical 
applications, i.e., it is safe and suitable for use in humans (Young S et al., 2005). Further, its 
isoelectric point (Ip) can be adjusted by modification of its residues, and positively charged 
gelatin can be impregnated with negatively charged substances (Ikada Y & Tabata Y, 1998), 
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such as nucleic acid (Kasahara H et al., 2003). Therefore, gelatin may be suitable as a vector 
for transfecting phagocytes ex vivo. 
Here, we describe a study aimed at examining the feasibility of a new concept for less-
invasive, cell-based gene therapy by means of ex vivo gene transfection into isolated 
phagocytes (macrophages/monocytes) using a gelatin carrier, followed by intravenous 
injection of the transfected phagocytes. The present method has significant advantages over 
conventional cell-based gene delivery (Panetta CJ et al., 2002; Xie Y et al., 2001), in that the 
intravenously injected cells (phagocytes) not only produce protein from the transfected 
gene, but also have the potential for high tissue targeting ability. This method should be 
suitable for clinical gene therapy. Indeed, its clinical efficacy in patients with cardiovascular 
disease has recently been reported (Komeda M et al., 2009; Marui A et al., 2007; Tabata Y, 
2009). 
2. Main body 
2.1 Methods 
This study was performed in accordance with the Guideline of Tokai University School of 
Medicine on Animal Use, which conforms to the NIH Guide for the Care and Use of 
Laboratory Animals, (DHEW publication No. (NIH) 86-23, Revised 1985, Offices of Science 
and Health Reports, DRR/NIH, Bethesda, MD, 20205). 
2.1.1 Animals 
One hundred and twenty-one Fisher rats (male, 10 weeks old, Clea Japan Inc., Tokyo) and 
61 nude SCID mice (male, 6 weeks old, Shizuoka Animal Center, Shizuoka, Japan) were 
used. Rats were anesthetized by inhalation of diethyl ether for harvesting of macrophages 
and with isofluran (1.5-3%) for thoracotomy, after which they were mechanically ventilated 
with a mixture of oxygen and nitrous oxide. Mice were anesthetized by intraperitoneal 
injection of sodium pentobarbital (40 mg/kg).  
A model of myocardial ischemia-reperfusion injury was prepared in 41 rats. The remaining 
80 rats were used for collecting activated macrophages. The heart was exposed via 
thoracotomy, and the proximal left anterior descending coronary artery was ligated (Gidh-
Jain M et al.,1996) for 180 min, followed by reperfusion. A model of hindlimb ischemia was 
prepared in 61 mice. The left femoral artery was ligated and resected (Takeshita S et al., 
1994). 
2.1.2 Cells 
Macrophages were obtained from 80 rats. Thioglycolate (4%, 8 ml) was injected into the 
peritoneal cavity, and after 4 days, peritoneal macrophages were collected (Ribeiro RA et 
al.,1991). Monocytes were obtained from peripheral blood of healthy volunteers. Leukocyte-
rich plasma was obtained by dextran 500 sedimentation and layered onto Nycoprep 1.068 
(Nycomed, Birmingham, UK). The monocyte-containing layer was aspirated, washed twice 
and allowed to adhere to the dish for 90 minutes. Fibroblasts (NIH 3T3, Invitrogen 
Corporation, Carlsbad, CA) were also used. The cells were resuspended in RPMI 1640 
medium (Sigma) containing 5% heat-inactivated fetal calf serum and cultured for 7-14 days. 
The cell viability and type were determined by trypan blue exclusion and by 
immunostaining using anti-macrophage antibody, up to 14 days. 
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2.1.3 Genes and vector 
Complementary DNA (cDNA) of green fluorescent protein (GFP), Renilla luciferase or 
human hst1/fibroblast growth factor 4 (FGF4) (Kasahara H et al., 2003) was inserted into the 
expression vector pRC/CMV (Invitrogen Corporation, Carlsbad, CA) and the constructs 
were designated as pRC/CMV-GFP, pRC/CMV-luciferase and pRC/CMV-HST1-10, 
respectively. Preparation and purification of the plasmid from cultures of pRC/CMV-GFP-, 
pRC/CMV-luciferase-, or pRC/CMV-HST1-10-transformed Escherichia coli were performed 
by equilibrium centrifugation in cesium chloride-ethidium bromide gradients. 
Gelatin was prepared from porcine skin (Tabata Y & Ikada Y, 1987). After swelling in water 
the gelatin particles used in this study were spheroids with a diameter of approximately 5-
30 µm, water content of 95%, and pI of 11. Gelatin (2 mg) was incubated with 50 µg of the 
plasmid for 7 days at 4 °C to make a gelatin-DNA complex (Tabata Y & Ikada Y, 1987).  
2.1.4 Ex vivo gene transfection 
Macrophages, monocytes, and fibroblasts (1 x 106) were cultured with the gelatin-DNA 
complex (2 mg of gelatin plus 50 µg of DNA) for 14 days on a culture dish (100 mm in 
diameter). Gene expression of GFP was evaluated by fluorescence microscopy and 
fluorescence-activated cell sorting. Luciferase activity in the cell lysate was evaluated with a 
photon counter system after cell lysis (Fukuyama N et al., 1996). 
2.1.5 Organ distribution of phagocytes injected intravenously and directly into 
ischemic muscle 
To examine tissue-targeting by intravenous injection of transfected phagocytes, the 
distribution of the cells into organs was evaluated by immunohistochemistry. In the rat 
model of myocardial ischemia-reperfusion injury, the GFP-gene-transfected macrophages 
(1.0 x 106 each) were injected into the superficial dorsal vein of the penis at the initiation of 
reperfusion (n=7 and 5, respectively). In the mouse model of hindlimb ischemia, the GFP-
gene-transfected monocytes (1.0 x 106) were injected into the caudal vein 14 days after 
induction of ischemia (n=5). To examine the tissue targeting by direct local injection of 
transfected phagocytes, the distribution of the cells into organs was also evaluated. In the rat 
model of myocardial ischemia-reperfusion injury (n=7) and the mouse model of hindlimb 
ischemia (n=5), the same numbers of transfected macrophages and monocytes were directly 
injected into ischemic myocardium and ischemic skeletal muscle, respectively. Tissue 
samples were obtained 24 hours after cell administration. Each tissue was homogenized and 
the homogenate was cytospun. Immunohistochemical analysis was done with anti-GFP 
antibody (GFP monoclonal antibody; Clontech, USA). GFP-positive macrophages were 
counted in each tissue and expressed as a percentage of total GFP-positive cells. 
2.1.6 Amelioration of ischemia by intravenous injection of angiogenic gene-
transfected phagocytes 
The angiogenic effect of intravenously injected FGF4-gene-transfected phagocytes on the 
ischemia models was evaluated. In the rat model of myocardial ischemia-reperfusion injury, 
FGF4-gene-transfected macrophages (n=5), non-transfected macrophages (1.0 x 106 each) 
(n=5), or saline (n=5) were injected into the superficial dorsal vein of the penis, or naked 
FGF4-DNA (50 µg) was injected directly into the ischemic myocardium (n=5), at the 
initiation of reperfusion. Fourteen days after the cell administration, blood flows in the 
ischemic and non-ischemic regions in the heart were evaluated with a noncontact laser 
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Doppler flowmeter (FLO-N1, Omegawave Corporation). Then, tissue samples were 
obtained and histological analysis was performed. In a mouse model of hindlimb ischemia, 
just after induction of ischemia, FGF4-gene-transfected monocytes (n=15), non-transfected 
monocytes (n=8) (1.0 x 106 each), or saline (n=10) were injected into the caudal vein, or 
naked FGF4-DNA (50 µg) was injected directly into the ischemic muscle (n=12). Fourteen 
days after induction of ischemia, blood flows in the limbs were evaluated with the 
noncontact laser Doppler flowmeter (FLO-N1, Omegawave Corporation).  
2.1.7 Histology 
Ten-micrometer sections were cut from formalin-fixed, paraffin-embedded tissue. Two 
sections were used for H.E. staining and Azan staining, and eight sections were used for 
immunohistochemical staining. Immunohistochemical staining was performed by an 
indirect immunoperoxidase method. Anti-GFP antibody, anti-Mac1 antibody (BMA 
Biomedicals Ag, Switzerland), and anti-CD31 antibody (Serotec, UK) were used as primary 
antibodies. Mac1-antigen is specific to macrophages/monocytes. Anti-Ig, peroxidase-linked 
species-specific F(ab')2 fragments (Amersham Pharmacia Biotech UK Ltd., UK), were used 
as a secondary antibody. Double staining was performed with alkaline staining and 
peroxidase staining. The density of vessels stained with von Willebrand factor-antibody was 
calculated by morphometric assessment in 16 randomly selected fields for each heart and 
expressed as number / mm2.  
2.1.8 Statistical analysis 
Data are presented as mean values±SD. Differences were assessed by means of ANOVA 
(analysis of variance) with Scheffe's multiple comparisons test. A value of P<0.05 was 
considered statistically significant. 
2.2 Results 
2.2.1 Ex vivo gene transfection 
We studied whether genes could be transfected into isolated rat macrophages, human 
monocytes, and mouse fibroblasts ex vivo by using gelatin. Transfection of the GFP gene 
into isolated rat macrophages (Figs. 1A and B) and human monocytes (Figs. 1C and D), but 
not into mouse fibroblasts (data not shown), was achieved by culture with gelatin-DNA 
complex for 14 days. The gene transfection efficiency into rat macrophages was 68±11% (30 
experiments, Fig. 2A) and that into human monocytes was 78±8% (30 experiments) as 
determined with a fluorescence-activated cell sorter. Sequential analysis after luciferase-
gene transfection into rat macrophages revealed high expression after 14 days of culture 
(Fig. 2B). 
2.2.2 Organ distribution of phagocytes injected intravenously or directly into ischemic 
muscle 
We studied quantitatively whether intravenously injected luciferase-gene-transfected 
phagocytes could target ischemic tissues (Table 1). In non-ischemic rats, the injected 
macrophages were found almost exclusively in the spleen (98±4%) (n=7, Table 1). In non-
ischemic mice, similar results were observed (n=7, data not shown). In a rat with myocardial 
ischemia-reperfusion injury, some of the intravenously injected macrophages were 
incorporated into the heart (Table 1). 
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Fig. 1. Fluorescent presentation of ex vivo gene transfection with gelatin-DNA complex in 
macrophages/monocytes as well as fibroblasts. Rat macrophages (A and B) and human 
monocytes (C and D) were cultured with gelatin-GFP-gene complex for 14 days. 
Transmittance microscopic images (A and C) and fluorescence images (B and D) of the cells 
are shown. Macrophages (B) and monocytes (D) show fluorescence due to GFP. Arrowheads 
indicate GFP-expressing cells. Arrows indicate gelatin particles themselves. Bars=20 µm 
(Fukuyama N et al., 2007).  
 
Fig. 2. Quantitative assessment of gene transfection into rat macrophages. A, Fluorescence-
activated cell sorting analysis of transfected macrophages done on day 14 of culture with 
reference to GFP-positive and Mac1-positive cells. B, Sequential changes of luciferase 
activity in cultured macrophages in the presence of luciferase-gene-gelatin complex. Values 
are mean±SD. The number of experiments is shown in parentheses (Fukuyama N et al., 
2007). 
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Table 1. Organ-distribution of phagocytes injected into the vein and into local tissue. Each 
value shows a distribution ratio (%) into organs of transfected macrophages/monocytes 
(mean±SD). i.v., intravenous injection into the vein; i.m. direct injection into the jeopardized 
muscle (Fukuyama N et al., 2007). 
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Fig. 3. Incorporation of injected macrophages into the heart. GFP-transfected macrophages 
were injected into the vein in a rat model of myocardial ischemia-reperfusion injury. A and 
B, Low-resolution images of ischemic myocardial tissue with hematoxylin-eosin staining 
and Azan staining, respectively. IVS, the interventricular septum; LV, the left ventricular 
free wall; RV, the right ventricular free wall. Original magnification x20. Bars=500 µm. C 
and D, Medium-and high-resolution images of ischemic myocardial tissue with 
hematoxylin-eosin staining; Original magnification x100 and x300; Bars=100 and 20 µm, 
respectively. E and F, Double immunohistochemical stainings of GFP- (red) and Mac1- 
(blue) antigens. Arrow indicates a GFP- and Mac1-antigen double-positive cell and 
arrowhead a Mac 1-antigen single-positive cell. Original magnification x100 and x400; 
Bars=100 and 10 µm, respectively. G, The time course of GFP-transfected macrophages (Mφ) 
accumulation into heart (Fukuyama N et al., 2007). 
The incorporation into the post-ischemic pericardium amounted to 13±6% (n=7) (non-
ischemic rats 0±0%, n=7, Table 1). The incorporated cells expressed GFP (Fig. 3). Fibrosis 
with inflammatory infiltrates was recognized in the anterior wall of the left ventricle, 
extending to the interventricular septum (Figs. 3A and B). These infiltrates were mainly 
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polymorphonuclear leukocytes and macrophages (Figs. 3C and D). Approximately 20 % of 
the macrophages showed GFP-positivity in this area (Figs. 3E and F). Similar tissue-
targeting by intravenously injected monocytes was confirmed in a mouse model with 
hindlimb ischemia (13±7%, n=7, Table 1). Furthermore, we studied whether local 
intramuscular injection increased the degree of tissue targeting (Table 1). After direct 
injection of phagocytes into ischemic muscle, 86±10% and 88±6% of the cells remained in the 
target tissue in the two models. Thirteen and 11% of phagocytes injected into the cardiac or 
hindlimb muscle migrated to the spleen. In the other organs, accumulation of phagocytes 
was negligible. 
2.2.3 Amelioration of ischemia by intravenously injected angiogenic-gene-transfected 
phagocytes 
In the rat model with myocardial ischemia-reperfusion injury, we studied the angiogenic  
effect of intravenously injected macrophages transfected with FGF4 gene by using gelatin. 
Intravenous injection of these macrophages (1.0 x 106) significantly increased the regional 
blood flow in the ischemic myocardium (78±7.1%, n=8, in terms of ischemic/non-ischemic 
myocardium flow ratio) compared with the other three treatments (P<0.05, ANOVA), that 
is, intravenous administration of saline (35±10%, n=8), intramuscular administration of 
naked DNA encoding FGF4 (50 µg, direct intramyocardial injection after thoracotomy) 
(58±5.3%, n=8), and intravenous administration of the same number of non-transfected 
macrophages (42±12%, n=8) (Fig. 4A). Histological analyses revealed angiogenesis in the 
ischemic tissue after the administration of transfected cells (Figs. 4B and C). Similar results 
were observed in the mouse model with hindlimb ischemia. Intravenous injection of FGF4-
gene-transfected monocytes (1.0 x 106) enhanced regional blood flow in the ischemic leg 
(Fig. 4D). The increase of blood flow in the mice with transfected monocytes (93±22% in 
terms of flow ratio in the ischemic/non-ischemic leg) was significantly larger than those 
obtained with the other three treatments described above (38±12, 55±12, and 39±15%, 
P<0.05, ANOVA). Neither lymph node swelling in any part of the body nor pathologic 
change in the spleen or lung, such as angioma or abnormal immune response, was found in 
any of the animals. 
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Fig. 4. Therapeutic effects of angiogenic-gene-transfected phagocytes on ischemia. FGF4-
transfected macrophages were injected into the vein or naked DNA encoding FGF4 was 
injected directly into the myocardium in a rat model of myocardial ischemia-reperfusion 
injury (A-C). FGF4-transfected monocytes were injected into the vein or naked DNA 
encoding FGF4 was injected directly into the ischemic muscle in a mouse model of hindlimb 
ischemia (D). A, Relative blood flow in the ischemic myocardium. Each flow represents a 
relative value with respect to non-ischemic region. The number of animals is shown in 
parentheses. B, Quantification of vessel density in the ischemic myocardium. The number of 
observation fields is shown in parentheses. C, Immunohistochemical staining in the 
ischemic myocardium with anti-CD31 antibody. D, Relative blood flow in the ischemic leg. 
Each flow represents a relative value with respect to non-ischemic leg. The number of 
animals is shown in parentheses. Control represents animals injected with saline into the 
vein; DNA, naked DNA encoding FGF4 was injected directly into the ischemic muscle; non-
Tf, non-transfected phagocytes were injected intravenously Tf, FGF4-gene-transfected 
phagocytes were injected intravenously. Values are mean±SD. P<0.05 vs *Cont, †DNA, and 
#non-Tf (ANOVA) (Fukuyama N et al., 2007). 
2.3 Discussion 
The advantages of the present method are as follows. First, genes can easily be transfected 
into phagocytes (macrophages/monocytes). In preliminary experiments, we found that 
genes can also be transfected into endothelial progenitor cells (Nagaya N et al., 2003). 
Compared with other transfection methods, the transfection efficiency was high (68±11%) 
and it is not necessary to use a potentially hazardous viral vector (Kobinger GP et al., 2004; 
Lei Y et al., 2004; Watson DJ et al., 2002). Second, the phagocytes can target pathologic 
tissues by chemotaxis even after intravenous injection, and targeting should be considerably 
improved if they are administered locally. Moreover, the injection is repeatable. We 
confirmed that the angiogenic gene-transfected phagocytes enhanced angiogenesis after 
ischemia-reperfusion injury in rat heart and ameliorated ischemia in a mouse hindlimb 
model. Gelatin prepared as described here is not rapidly degraded in the human body, and 
should be effective for prolonged transfection gene therapy, as well as for drug delivery 
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systems, etc.. This method appears to be suitable for safe and effective cell-based gene 
therapy.  
The injected phagocytes migrated into pathologic tissues, presumably in response to the 
release of cytokines such as monocyte chemoattractant protein 1 by injured endothelial cells 
(Yoshimura T & Leonard EJ, 1990). Adhesion molecules such as P-selectin (Ikada Y et al., 
2002) are probably involved in the recruitment of phagocytes to the vessel wall. The injected 
phagocytes also migrated to the spleen, but no pathologic change was found in the spleen. 
The present method has several advantages over conventional methods of cell-based  
gene therapy, such as fibroblast-based and smooth muscle cell-based approaches (Koch K-C 
et al., 2006; Ott HC et al., 2005; Xie Y et al., 2001). For example, monocytes do not aggregate 
in vessels, whereas fibroblasts or smooth muscle cells cannot be injected intravenously 
because of aggregation. The transfected phagocytes not only synthesize protein from the 
transfected gene, but also are partially targeted to the impaired tissue. In addition, the 
transfection rate was better than those of methods such as lipofection, viral vectors and 
electroporation (Kobinger GP et al., 2004; Veit K et al., 1999). The newly developed 
technique of nucleofection has a transfection efficiency of 40-70% (Maasho K et al., 2004), 
which is similar to that of our method, but our procedure is easier to use (Maasho K et al., 
2004; Mertz KD et al., 2002).  
3. Conclusion 
The therapeutic effect obtained here (intravenous administration of phagocytes transfected 
ex vivo with FGF4 DNA/biodegradable gelatin complex) was superior to that of 
conventional gene therapy, which we reported previously, i.e., intramuscular injection of 
naked DNA, in heart and leg ischemia models. The major disadvantage of our method is the 
cell preparation time of 2 weeks before therapy can be started, and further work is needed to 
speed up this process. However, our results suggest that this method may an effective 
therapeutic option from the viewpoint of regenerative medicine. 
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